Auto-Injectors Market (By Product Type: Disposable Auto-Injectors, Reusable Auto-Injectors; By Disease Indication: Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other Therapies; By End-use: Home Care Settings, Hospitals & Clinics, Ambulatory Surgical Centers) - Global Industry Size, Share, Trends and Forecast 2019 - 2026

Category : Healthcare and Pharmaceuticals | Published at : August-2019 | Delivery Format : PDF | Status: Published | Pages : 190


According to Acumen Research and Consulting, the global auto-injectors market size is expected to worth around US$ 3.2 billion by 2026 growing at outstanding CAGR of 19.6% over the forecast time period 2019 to 2026.

The report provides analysis of global Auto-Injectors market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year. 

Market Insights

Increased anaphylactic shock incidence, an knowledge of the instruments and habits of nurses to self-administer injections are the main variables which drive the industry as a whole. Self-injectors are chosen over standard machines because they allow effective and better drug delivery and fresh formulations. Product technological advances are expected to increase development. Humira by AbbVie, Inc. for example, comes with a lock feature and begin and end alerts for injection. Auto-injectors give numerous benefits such as reducing needles-related phobia anxiety, reducing the chance of needlestick injuries, maintaining dose consistency and helping increase the efficacy, which, in turn, helps to grow. Drug delivery is more regulated than manual injections from an auto-injector.

The innovations in auto-injector products and computer features are the main variables that drive the development of the auto-injector industry. Betaconnect, an auto-injector electronic for rebounding multiple sclerosis (RRMS) therapy, was introduced in September 2015 by Bayer HealthCare. These auto-injectors provide full dosage of medicines for better adherence and possibly reduce general costs. The SHL Group provides a range of autoinjectors, such as bigger quantities, elevated viscosity and others, to meet changing injection requirements. Auto-injector companies focus on enhancing auto-injector features to enhance the handling and therapy of diseases. The location of injection of a certain drug is selected depending on the nature of the drug, but is usually given intra-muscular. Auto-injectors are less painful than syringes, increasing demand. Alternatives such as verbal pills can, however, hinder development.

Device innovations are also expected to promote development. For example, Bayer HealthCare introduced an electronic auto-injector in September 2015 for the treatment of various relapse-emitting sclerosis, which provides full drug dosage to increase adherence and possibly reduce general costs. The SHL group provides different kinds of high volume and high-viscosity auto-injectors.

Segment Analysis

The industry is divided into products that include disposable and reusable automotive injectors. Disposable auto-injectors were the biggest category in 2018 because of their ease of operation, comfort and patient choice.

Two types are accessible for reusable auto-injectors, including pre-filled and void auto-injectors. Prefilled auto-injectors were the largest segment in 2018 and will remain dominant during the forecast period. They are equipped with conventional prefilled drug bottles and are simple to use. The biggest benefit of prefilled syringes is to eliminate dose mistake. The industry is divided into rheumatoid arthritis, various sclerosis, diabetes, anaphylaxis and other therapy, according to illness sign. The section of anaphylaxis was the biggest share in 2018. This important proportion can be ascribed to the increasing incidence of anaphylactic reactions from meat, drugs, latex and insect stings.

According to the Asthma and Allergy Foundation of America, the most prevalent health problems influencing kids in the United States are allergic conditions. In 2015, 8.8 million kids were allergic to skin and 4.2 million were allergic to meat. Allergy is Europe's most prevalent chronic disease.  The home care sector is anticipated to appear over the prediction era as the fastest increasing section. Increased home healthcare introduction, combined with the increasing incidence of diabetes, due to the increasing geriatric population can be ascribed to the highest development in this section. The hospital sector is expected to develop gradually during the forecast period, due to an rise in the amount of anaphylactic and multiple sclerosis clients.  Most of the pharmaceutical companies move to biologics and vaccines from tiny molecules motivated by the enhanced effectiveness and immunogenicity of large molecules. Biological growth is growing, which is an important factor for identifying corporate pipelines, procurement policies, and the introduction of biological products in developed U.S. and European markets. The World Health Organization states that 5% of the population suffers from autoimmune illnesses. New drug classifications may be developed to provide fresh understanding and fresh therapeutic agents to curate illnesses. About 2/3 of the fresh drugs to be introduced in the next few years are biological and continuous release drugs and will in the near future boost the development of self-injectors.

Regional Stance

North America dominated the industry in 2018, and its location is anticipated to remain over the forecast period. This can be ascribed to progress in the technology of medical devices, sophisticated health infrastructure and the strong demand for quality products. Allergy is the sixth major source of chronic disease in the U.S., according to the Asthma and Allergy Foundation of America. In 2015, approximately 8.8 million kids had skin allergies and 4.2 million were allergic to meat. Every year around 200,000 individuals, according to Food Allergy Research & Education, need emergency medical care for allergic food responses. The above variables are therefore expected to increase supply in this area. Asia Pacific is expected to develop at the most rapid CAGR owing to variables such as rising diabetic incidence and anaphylaxis caused by food allergies in nations including India, China, Japan, Singapore, and Australia. Increased incidence of type 1 diabetes is expected to boost market growth. In 2017, some 50,000 young people under the era of 20 live with type 1 diabetes in China. With good production facilities available and low-cost labour available, multi-national businesses concentrate on developing markets like Asia Pacific. Pharmaceutical companies have their manufacturing facilities in Asian nations because of the simple accessibility of qualified work and small raw materials costs. The approach used by businesses in these nations involves growing revenues and extending company by marketing products in a geographical way.

Market Segmentation

Global Auto-Injectors Market, by Product Type

  • Disposable Auto-Injectors
  • Reusable Auto-Injectors
    • PrefilledAuto-injectors
    • EmptyAuto-injectors

 Global Auto-Injectors Market, by Disease Indication    

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies

Global Auto-Injectors Market, by End-use           

  • Home Care Settings
  • Hospitals & Clinics
  • Ambulatory Surgical Centers

 Global Auto-Injectors Market, by Geography

  • North America.
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “Auto-Injectors Market Size, Share & Trends Analysis Report by Product Type, Disease Indication, End-Use and Region - Global Industry Size, Share, Trends and Forecast 2019 - 2026” offers detailed insights on global auto-injectors market segments with market dynamics and their impact. The report also covers basic technology development policies.

Key Players & Strategies

The key players operating in the market include Eli Lilly, Teva Pharmaceutical, Amgen, Pfizer, Inc., Owen Mumford, Ypsomed, Scandinavian Health Ltd., AbbVie, Inc., Biogen Idec, Mylan N.V., and Sanofi. Major competitors are concentrating on fresh brand launches, purchases, developments in current products and techniques and other policies to grow and reinforce their business. The most important strategic inferences were technological partnerships, mergers & acquisitions, inorganic growing companies and product range, followed by main competitors in the sector.

Key competition-enhancing parameters are quick adoption of sophisticated healthcare systems. In fact, significant competitors often engage in fusions and purchases together with launching fresh products with a view to retaining and diversifying the brand portfolio. The main strategic activities for major players in the sector were effective inorganic development through merger and takeover, technological development to improve surge transport capacity together with the expansion of production facilities for economies of scale.

Frequently Asked Questions

Research study by Acumen Research and Consulting, the auto-injectors market size is anticipated to reach around US$ 3.2 billion in 2026.

The auto-injectors market is anticipated to grow over 19.6% CAGR during the forecast period 2019 to 2026.

The anaphylaxis segment was the biggest share in 2018.

North America held maximum share in 2018 for auto-injectors market.

Asia Pacific is projected to grow at a fast pace during forecast period in the auto-injectors market.

The auto-injectors market is segmented into North America, Europe, Asia Pacific, Latin America and The Middle East & Africa (LAMEA).

Eli Lilly, Teva Pharmaceutical, Amgen, Pfizer, Inc., Owen Mumford, Ypsomed, Scandinavian Health Ltd., and AbbVie, Inc. are the top players operating in the auto-injectors market.

Cart Summary